Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

2.

A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.

Sanborn RE, Ross HJ, Aung S, Acheson A, Moudgil T, Puri S, Hilton T, Fisher B, Coffey T, Paustian C, Neuberger M, Walker E, Hu HM, Urba WJ, Fox BA.

J Immunother Cancer. 2017 Dec 19;5(1):103. doi: 10.1186/s40425-017-0306-6.

3.

A Milestone for CAR T Cells.

Tran E, Longo DL, Urba WJ.

N Engl J Med. 2017 Dec 28;377(26):2593-2596. doi: 10.1056/NEJMe1714680. Epub 2017 Dec 10. No abstract available.

PMID:
29226781
4.

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.

Cell. 2017 Nov 2;171(4):934-949.e15. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.

PMID:
29033130
5.

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA.

Clin Cancer Res. 2017 Oct 15;23(20):6165-6177. doi: 10.1158/1078-0432.CCR-16-2677. Epub 2017 Aug 28.

PMID:
28855348
6.

Multiparametric immune profiling in HPV- oral squamous cell cancer.

Feng Z, Bethmann D, Kappler M, Ballesteros-Merino C, Eckert A, Bell RB, Cheng A, Bui T, Leidner R, Urba WJ, Johnson K, Hoyt C, Bifulco CB, Bukur J, Wickenhauser C, Seliger B, Fox BA.

JCI Insight. 2017 Jul 20;2(14). pii: 93652. doi: 10.1172/jci.insight.93652. [Epub ahead of print]

7.

The Effect of Superparamagnetic Iron Oxide Nanoparticle Surface Charge on Antigen Cross-Presentation.

Mou Y, Xing Y, Ren H, Cui Z, Zhang Y, Yu G, Urba WJ, Hu Q, Hu H.

Nanoscale Res Lett. 2017 Dec;12(1):52. doi: 10.1186/s11671-017-1828-z. Epub 2017 Jan 19.

8.

Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression.

Yu G, Li Y, Cui Z, Morris NP, Weinberg AD, Fox BA, Urba WJ, Wang L, Hu HM.

Sci Rep. 2016 Nov 22;6:37558. doi: 10.1038/srep37558.

9.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, Maio M, Urba WJ, Gangadhar TC, Suryawanshi S, Neely J, Jure-Kunkel M, Krishnan S, Kohrt H, Sznol M, Levy R.

Clin Cancer Res. 2017 Apr 15;23(8):1929-1936. doi: 10.1158/1078-0432.CCR-16-1272. Epub 2016 Oct 18.

10.

Unmasking PD-1 Resistance by Next-Generation Sequencing.

Bifulco CB, Urba WJ.

N Engl J Med. 2016 Sep 1;375(9):888-9. doi: 10.1056/NEJMe1606042. No abstract available.

PMID:
27579640
11.

Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine.

Page DB, Hulett TW, Hilton TL, Hu HM, Urba WJ, Fox BA.

J Immunother Cancer. 2016 May 17;4:25. doi: 10.1186/s40425-016-0130-4. eCollection 2016. Review.

12.

Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.

Koguchi Y, Hoen HM, Bambina SA, Rynning MD, Fuerstenberg RK, Curti BD, Urba WJ, Milburn C, Bahjat FR, Korman AJ, Bahjat KS.

Cancer Res. 2015 Dec 1;75(23):5084-92. doi: 10.1158/0008-5472.CAN-15-2303.

13.

OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.

Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, Gough MJ, Fox BA, Weinberg AD, Urba WJ.

Oral Oncol. 2016 Jan;52:1-10. doi: 10.1016/j.oraloncology.2015.11.009. Epub 2015 Nov 21. Review.

PMID:
26614363
14.

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.

Feng Z, Puri S, Moudgil T, Wood W, Hoyt CC, Wang C, Urba WJ, Curti BD, Bifulco CB, Fox BA.

J Immunother Cancer. 2015 Oct 20;3:47. doi: 10.1186/s40425-015-0091-z. eCollection 2015.

15.

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD.

JAMA Oncol. 2015 Jul;1(4):433-40. doi: 10.1001/jamaoncol.2015.1184.

PMID:
26181250
16.

Clinical deployment of antibodies for treatment of melanoma.

Curti BD, Urba WJ.

Mol Immunol. 2015 Oct;67(2 Pt A):18-27. doi: 10.1016/j.molimm.2015.01.025. Epub 2015 Mar 6. Review.

PMID:
25746916
17.

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program.

Payne R, Glenn L, Hoen H, Richards B, Smith JW 2nd, Lufkin R, Crocenzi TS, Urba WJ, Curti BD.

J Immunother Cancer. 2014 May 14;2:13. doi: 10.1186/2051-1426-2-13. eCollection 2014.

18.

Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells.

Ye W, Xing Y, Paustian C, van de Ven R, Moudgil T, Hilton TL, Fox BA, Urba WJ, Zhao W, Hu HM.

J Transl Med. 2014 Apr 16;12:100. doi: 10.1186/1479-5876-12-100.

19.

At the bench: adoptive cell therapy for melanoma.

Urba WJ.

J Leukoc Biol. 2014 Jun;95(6):867-74. doi: 10.1189/jlb.0513301. Epub 2014 Mar 21. Review.

PMID:
24659789
20.

OX40 is a potent immune-stimulating target in late-stage cancer patients.

Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD.

Cancer Res. 2013 Dec 15;73(24):7189-7198. doi: 10.1158/0008-5472.CAN-12-4174. Epub 2013 Oct 31.

21.

A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS.

J Immunother. 2013 Nov-Dec;36(9):490-5. doi: 10.1097/CJI.0000000000000003.

PMID:
24145360
22.

Melanoma: more answers, more questions.

Urba WJ.

Oncologist. 2013 Jun;18(6):658-60. doi: 10.1634/theoncologist.2013-0212. No abstract available.

23.

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.

Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ.

Ann N Y Acad Sci. 2013 Jul;1291:1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17. Review.

24.

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.

Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J, Fox BA.

J Transl Med. 2013 Mar 3;11:54. doi: 10.1186/1479-5876-11-54.

25.

Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs.

Yi Y, Zhou Z, Shu S, Fang Y, Twitty C, Hilton TL, Aung S, Urba WJ, Fox BA, Hu HM, Li Y.

Oncoimmunology. 2012 Sep 1;1(6):976-978.

26.

Integrating new therapies in the treatment of advanced melanoma.

Curti BD, Urba WJ.

Curr Treat Options Oncol. 2012 Sep;13(3):327-39. doi: 10.1007/s11864-012-0201-9. Review.

PMID:
22743761
27.

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.

Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, Miller W, Payne R, Glenn L, Bageac A, Urba WJ.

Sci Transl Med. 2012 Jun 6;4(137):137ra74. doi: 10.1126/scitranslmed.3003649.

28.

An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer.

Morrow PK, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN.

Cancer. 2012 Sep 1;118(17):4098-104. doi: 10.1002/cncr.26730. Epub 2012 Jan 26.

29.

Active-specific immunotherapy for non-small cell lung cancer.

Winter H, van den Engel NK, Rusan M, Schupp N, Poehlein CH, Hu HM, Hatz RA, Urba WJ, Jauch KW, Fox BA, Rüttinger D.

J Thorac Dis. 2011 Jun;3(2):105-14. doi: 10.3978/j.issn.2072-1439.2010.12.06.

30.

Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy.

Li Y, Wang LX, Pang P, Cui Z, Aung S, Haley D, Fox BA, Urba WJ, Hu HM.

Clin Cancer Res. 2011 Nov 15;17(22):7047-57. doi: 10.1158/1078-0432.CCR-11-0951. Epub 2011 Nov 8.

31.

Science gone translational: the OX40 agonist story.

Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD.

Immunol Rev. 2011 Nov;244(1):218-31. doi: 10.1111/j.1600-065X.2011.01069.x. Review.

32.

Multiple vaccinations: friend or foe.

Church SE, Jensen SM, Twitty CG, Bahjat K, Hu HM, Urba WJ, Fox BA.

Cancer J. 2011 Sep-Oct;17(5):379-96. doi: 10.1097/PPO.0b013e3182346320. Review.

33.

Redirecting T cells.

Urba WJ, Longo DL.

N Engl J Med. 2011 Aug 25;365(8):754-7. doi: 10.1056/NEJMe1106965. Epub 2011 Aug 10. No abstract available.

PMID:
21830939
34.

The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program.

Balwit JM, Hwu P, Urba WJ, Marincola FM.

J Transl Med. 2011 Jan 31;9:18. doi: 10.1186/1479-5876-9-18. Review.

35.

Signaling through OX40 enhances antitumor immunity.

Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA.

Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Review.

36.

Improved survival with ipilimumab in patients with metastatic melanoma.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.

N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

37.

CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.

Wang LX, Li Y, Yang G, Pang PY, Haley D, Walker EB, Urba WJ, Hu HM.

Eur J Immunol. 2010 May;40(5):1375-85. doi: 10.1002/eji.200839210.

38.

Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study.

Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM.

Clin Genitourin Cancer. 2009 Oct;7(3):E58-65. doi: 10.3816/CGC.2009.n.025.

PMID:
19815483
39.

Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

Petrausch U, Poehlein CH, Jensen SM, Twitty C, Thompson JA, Assmann I, Puri S, LaCelle MG, Moudgil T, Maston L, Friedman K, Church S, Cardenas E, Haley DP, Walker EB, Akporiaye E, Weinberg AD, Rosenheim S, Crocenzi TS, Hu HM, Curti BD, Urba WJ, Fox BA.

Curr Mol Med. 2009 Aug;9(6):673-82. Review.

40.

Cross-presentation of tumor associated antigens through tumor-derived autophagosomes.

Li Y, Wang LX, Pang P, Twitty C, Fox BA, Aung S, Urba WJ, Hu HM.

Autophagy. 2009 May;5(4):576-7. Epub 2009 May 6.

41.

Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.

Walker EB, Miller W, Haley D, Floyd K, Curti B, Urba WJ.

Clin Cancer Res. 2009 Apr 1;15(7):2541-51. doi: 10.1158/1078-0432.CCR-08-2806. Epub 2009 Mar 24.

42.

Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.

Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ.

J Urol. 2008 Nov;180(5):2011-7; discussion 2017-8. doi: 10.1016/j.juro.2008.07.048. Epub 2008 Sep 17.

PMID:
18801509
43.

Efficient cross-presentation depends on autophagy in tumor cells.

Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM.

Cancer Res. 2008 Sep 1;68(17):6889-95. doi: 10.1158/0008-5472.CAN-08-0161.

44.

Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization.

Walker EB, Haley D, Petrausch U, Floyd K, Miller W, Sanjuan N, Alvord G, Fox BA, Urba WJ.

Clin Cancer Res. 2008 Aug 15;14(16):5270-83. doi: 10.1158/1078-0432.CCR-08-0022.

45.

Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.

Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB 3rd, Yu M, Caterini J, Kim-Schulze S, Debenedette M, Salha D, Vogel T, Elias I, Berinstein NL.

Clin Cancer Res. 2008 Aug 1;14(15):4843-9. doi: 10.1158/1078-0432.CCR-08-0276.

46.

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.

Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS.

J Clin Oncol. 2008 May 10;26(14):2292-8. doi: 10.1200/JCO.2007.13.3165.

47.

Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.

Clark JI, Mehrabi J, Sosman JA, Logan TF, Margolin KA, Dutcher JP, Urba WJ, Ernstoff MS, McDermott DF, Lau AM, Atkins MB.

J Immunother. 2007 Nov-Dec;30(8):839-46.

PMID:
18049336
48.
49.

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.

Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW.

Clin Cancer Res. 2007 Jul 1;13(13):3883-91.

50.

Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.

Meijer SL, Dols A, Jensen SM, Hu HM, Miller W, Walker E, Romero P, Fox BA, Urba WJ.

J Immunother. 2007 Jul-Aug;30(5):533-43.

PMID:
17589294

Supplemental Content

Support Center